Data presented at the meeting of the American Society of Hematology last week by bluebird bio and Celgene researchers on their chimeric antigen receptor T-cell therapy candidate bb2121 showed the therapy achieved a 94% response rate from 18 patients with advanced multiple myeloma, with 56% maintaining remission 40 weeks after treatment on average.
The FDA has approved an investigational device exemption for Cerus' late-stage ReCePI study, allowing the firm to progress with the evaluation of its Intercept blood system for red blood cells to be used in patients receiving complex cardiac surgery. Development of the system is supported by the Biomedical Advanced Research and Development Authority.
The CMS' clinical lab fee schedule for 2018 would make cuts to 75% of all tests, creating "new barriers to patient access to care," AACC says. "One unintended consequence of the proposed CLFS is that it may force many laboratories to stop or significantly curtail their testing, particularly rural hospitals, small health clinics, and physician office laboratories," AACC warned the CMS.
The prevalence of multimorbidity among Americans living with HIV and being treated was found to have increased from 8.2% in 2000 to 22.4% in 2009, according to a study of data from 22,969 adult persons living with HIV. The research, published in the journal Clinical Infectious Diseases, evaluated multimorbidity trends among PLWH taking antiretroviral therapy who had age-associated co-existing conditions.
Nearly 90 blood cancer research projects in St. Louis will share a total of over $1.7 million in grants from the Leukemia & Lymphoma Society. Among the 87 recipients are four researchers at Washington University School of Medicine.
Researchers with the University of California at San Diego School of Medicine found that high levels of the ADAR1 enzyme are associated with decreased survival rates among multiple myeloma patients, according to a study in the journal Nature Communications. Regeneration of multiple myeloma cells was reduced in mice without the enzyme.
A study supported by the National Heart, Lung, and Blood Institute found that the delivery of powerful clot-busting drugs via catheter for the prevention of post-thrombotic syndrome in patients with deep vein thrombosis was associated with minimal benefit, based on data for almost 700 participants with DVT. The study in The New England Journal of Medicine found similar rates of post-thrombotic syndrome with and without the procedure, but rates of dangerous bleeding were higher with the procedure.
Engineers at the University of California at San Diego have developed a 3D-printed smartphone case and companion app that can check and record the user's blood glucose levels. A permanent sensor is embedded in the case and works with single-use enzyme-packed pellets in an attached 3D-printed stylus to measure glucose levels in a drop of blood and transmit the information via Bluetooth to the app.
Health officials in Pakistan say HIV cases number 133,000 in the country and are increasing. The government of Khyber Pakhtunkhwa province is starting an HIV/AIDS awareness campaign, and a new center focused on HIV/AIDS care is set to open there.
Fate Therapeutics and the University of California at San Diego entered an agreement to develop chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. Financial details of the deal were not disclosed.
- Page 1